StockTipsArenaBeta

BUY Dr. Reddy's Laboratories Limited — Osho Krishan, Angel One

BUYDr. Reddy's Laboratories Limited
Dr. Reddy's Laboratories share price target & all analyst calls

byOsho Krishan, Angel OneHorizon: NA (inferred Swing (≤2wk))3 Aug 2026via NDTV Profit

Entry₹1,174Inferred
Target₹1,290
Total upside +9.88% (call closed)
Stop lossNot given
At expiry₹1,19217 Aug 2026, 3:30 pm
Expired+1.53%auction close
Follow Osho Krishan for new calls(29% target hit, 165 closed calls)Get alertsWatch DRREDDY for new buy/sell callsGet alertsSee 4 active Swing calls on DRREDDY

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

Frozen at close · 17 Aug 2026
3 supporting3 neutral2 opposing
Supports the BUY call (3)

Dr. Reddy's Laboratories has received U.S. FDA approval for its rituximab biosimilar. Fresenius Kabi will exclusively commercialize the product in the United States. This approval strengthens Dr. Redd

BSE · Company Update·1 Aug · 2w ago

(opens in new tab)

Dr Reddy's Laboratories Ltd received approval for its gonorrhea drug from Thailand, following a US nod, as reported by Business Standard.

BSE · Company Update·28 Jul · 3w ago

(opens in new tab)

1 advisor has an active short-term BUY call on this stock

Advisor consensus · adjacent horizon·23 Jul · 4w ago

Neutral / worth noting (3)

Dr Reddy's ends distribution deal with Novartis India after ownership change

NewsCnbc-Tv18·7 Aug · 1w ago

(opens in new tab)

Dr Reddy’s Srikakulam facility in Andhra Pradesh gets UFDA Form 483 with 3 observations

NewsCnbc-Tv18·30 Jul · 3w ago

(opens in new tab)

Dr. Reddy's Laboratories Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.

NSE · Outcome of Board Meeting·22 Jul · 4w ago

(opens in new tab)
Weighs against the BUY call (2)

Dr. Reddy's Laboratories shares will react to weak Q1 after US-listed ADR falls 10%

NewsCnbc-Tv18·23 Jul · 4w ago

(opens in new tab)

Dr Reddy's Q1 Results: Semaglutide API provision weighs on profit; margin halves

NewsCnbc-Tv18·22 Jul · 4w ago

(opens in new tab)

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Dr. Reddy's Laboratories

All analyst calls on Dr. Reddy's Laboratories

More from Osho Krishan, Angel One

Every call and its outcome